UNICYCIVE THERAPEUTICS INC (UNCY) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:UNCY • US90466Y2028

6.92 USD
+0.47 (+7.29%)
At close: Feb 3, 2026
6.83 USD
-0.09 (-1.3%)
After Hours: 2/3/2026, 8:00:02 PM
Fundamental Rating

2

UNCY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. While UNCY seems to be doing ok healthwise, there are quite some concerns on its profitability. UNCY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • UNCY had negative earnings in the past year.
  • UNCY had a negative operating cash flow in the past year.
  • UNCY had negative earnings in each of the past 5 years.
  • UNCY had a negative operating cash flow in each of the past 5 years.
UNCY Yearly Net Income VS EBIT VS OCF VS FCFUNCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • UNCY has a Return On Assets of -119.44%. This is in the lower half of the industry: UNCY underperforms 78.63% of its industry peers.
  • UNCY has a Return On Equity of -509.00%. This is in the lower half of the industry: UNCY underperforms 75.00% of its industry peers.
Industry RankSector Rank
ROA -119.44%
ROE -509%
ROIC N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UNCY Yearly ROA, ROE, ROICUNCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for UNCY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UNCY Yearly Profit, Operating, Gross MarginsUNCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

  • UNCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for UNCY has been increased compared to 1 year ago.
  • UNCY has more shares outstanding than it did 5 years ago.
  • UNCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UNCY Yearly Shares OutstandingUNCY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
UNCY Yearly Total Debt VS Total AssetsUNCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • UNCY has an Altman-Z score of -3.88. This is a bad value and indicates that UNCY is not financially healthy and even has some risk of bankruptcy.
  • UNCY has a Altman-Z score of -3.88. This is comparable to the rest of the industry: UNCY outperforms 43.70% of its industry peers.
  • UNCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.88
ROIC/WACCN/A
WACC8.93%
UNCY Yearly LT Debt VS Equity VS FCFUNCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 1.28 indicates that UNCY should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.28, UNCY is doing worse than 82.44% of the companies in the same industry.
  • UNCY has a Quick Ratio of 1.28. This is a normal value and indicates that UNCY is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.28, UNCY is not doing good in the industry: 81.68% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.28
UNCY Yearly Current Assets VS Current LiabilitesUNCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 61.65% over the past year.
  • UNCY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)61.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, UNCY will show a very strong growth in Earnings Per Share. The EPS will grow by 21.11% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y82.78%
EPS Next 2Y36.89%
EPS Next 3Y46.87%
EPS Next 5Y21.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UNCY Yearly Revenue VS EstimatesUNCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
UNCY Yearly EPS VS EstimatesUNCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • UNCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UNCY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UNCY Price Earnings VS Forward Price EarningsUNCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UNCY Per share dataUNCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as UNCY's earnings are expected to grow with 46.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.89%
EPS Next 3Y46.87%

More info and screens

0

5. Dividend

5.1 Amount

  • UNCY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (2/3/2026, 8:00:02 PM)

After market: 6.83 -0.09 (-1.3%)

6.92

+0.47 (+7.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)N/A
Inst Owners30.38%
Inst Owner Change2.22%
Ins Owners2.93%
Ins Owner Change0%
Market Cap148.71M
Revenue(TTM)N/A
Net Income(TTM)-37.82M
Analysts82.86
Price Target47.43 (585.4%)
Short Float %7.65%
Short Ratio3.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP-2.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-57.77%
Min EPS beat(2)-183.22%
Max EPS beat(2)67.68%
EPS beat(4)2
Avg EPS beat(4)-94.53%
Min EPS beat(4)-285.83%
Max EPS beat(4)67.68%
EPS beat(8)3
Avg EPS beat(8)-69%
EPS beat(12)3
Avg EPS beat(12)-55.72%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-26.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-12.92%
EPS NY rev (3m)-4.03%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 20.01
P/tB 20.01
EV/EBITDA N/A
EPS(TTM)-3.95
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0
BVpS0.35
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -119.44%
ROE -509%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 327.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.28
Altman-Z -3.88
F-Score4
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)153.54%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34%
EPS Next Y82.78%
EPS Next 2Y36.89%
EPS Next 3Y46.87%
EPS Next 5Y21.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.38%
EBIT Next 3Y175.15%
EBIT Next 5YN/A
FCF growth 1Y-56.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.29%
OCF growth 3YN/A
OCF growth 5YN/A

UNICYCIVE THERAPEUTICS INC / UNCY FAQ

What is the fundamental rating for UNCY stock?

ChartMill assigns a fundamental rating of 2 / 10 to UNCY.


What is the valuation status for UNCY stock?

ChartMill assigns a valuation rating of 1 / 10 to UNICYCIVE THERAPEUTICS INC (UNCY). This can be considered as Overvalued.


How profitable is UNICYCIVE THERAPEUTICS INC (UNCY) stock?

UNICYCIVE THERAPEUTICS INC (UNCY) has a profitability rating of 0 / 10.


Is the dividend of UNICYCIVE THERAPEUTICS INC sustainable?

The dividend rating of UNICYCIVE THERAPEUTICS INC (UNCY) is 0 / 10 and the dividend payout ratio is -2.89%.